Get started
Markets US Stocks Health Technology Medical Specialties

Pulse Biosciences, Inc PLSE

PLSENASDAQ
PLSE
Pulse Biosciences, IncNASDAQ
See more on advanced chartSee more on advanced chart
 
No trades
Upcoming Earnings
EPS
Market Cap
Div Yield
P/E
Upcoming Earnings
EPS
Market Cap
Div Yield
P/E
See more on advanced chartSee more on advanced chart
Overview
News Ideas Financials Technicals Forecast

PLSE chart

Ideas

PLSE top authors
Alamento
Alamento Premium
Follow Following Unfollow
PLSE 30% gain or more Coming?!
PLSE
, 1D
PLSE: PLSE 30% gain or more Coming?!
Updated 

This stock is a little low on the volume so I wouldn't throw lots at it but I see a good short term winner if it goes to $15 like I think it will.

BO WL. C&H
PLSE
, 1WLong
PLSE: BO WL. C&H

17.76% Short float

$PLSE - on watch for potential breakout.
PLSE
, 1W
PLSE: $PLSE - on watch for potential breakout.

Was targeted by Citron shorts. Due for recovery if earnings well perceived by market.

PLSE symmetrical triangle forming
PLSE
, D
PLSE: PLSE symmetrical triangle forming

Watching for a buying opportunity in the $13 range, with a target of $27

Cash bleeding company on a bullish trend how far can this run?
PLSE
, D
PLSE: Cash bleeding company on a bullish trend how far can this run?

PLSE has been bleeding cash for a while now but it has attracted investments from two investors providing cash infusion to help it stay afloat on early February. This is when the stock broke out and has been trending up since then. Even though doom and gloom was predicted for PLSE here on Feb 23 2017 stock has moved up by $7 since then. Yesterday I was expecting a...

PLSE Short Idea Fail
PLSE
, D
PLSE: PLSE Short Idea Fail

Was looking to take this short under $9.00 level.... HAHAHAHAHAH

Technicals

Analyst rating

Financials

Valuation
Enterprise Value/EBITDA, TTM —
Enterprise Value, FQ —
Market Cap — Basic —
Number of Employees —
Number of Shareholders —
Price/Earnings, TTM —
Price/Revenue, TTM —
Price/Book Ratio, FY —
Price/Sales Ratio, FY —
Balance Sheet
Current Ratio, FQ —
Debt to Equity, FQ —
Net Debt, FQ —
Quick Ratio, FQ —
Total Assets, FQ —
Total Debt, FQ —
Operating Metrics
Return on Assets, TTM —
Return on Equity, TTM —
Return on Invested Capital, TTM —
Revenue per Employee, TTM —
Price History
Average Volume (10 day) —
Beta - 1 Year —
Price - 52 Week High —
Price - 52 Week Low —
Dividends
Dividends Paid, FY —
Dividends per Share, FY —
Expected Annual Dividends —
Dividends Yield —
Margins}
Net Margin, TTM —
Gross Margin, TTM —
Operating Margin, TTM —
Pretax Margin, TTM —
Income Statement
Basic EPS, Net Income —
Earnings per Share, Basic, TTM —
EBITDA, TTM —
Gross Profit, FY —
Last Annual EPS —
Last Annual Revenue, FY —
Net Income, FY —
Total Revenue, FY —
Free Cash Flow, TTM —
More financials

Profile

Sector: Health Technology
Industry: Medical Specialties
Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments uses a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Hayward, CA.

News flow

More news